Early Prediction of Severe Sepsis
To derive a biomarker to allow the identification of patients with confirmed sepsis, and risk stratify patients at risk of developing severe sepsis
A Prospective, multi-centre cohort observational study
Professor Tim Walsh, Critical Care Research Group
Professor Tim Walsh
Patients who present to the Emergency Department with suspected sepsis
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax
Evaluating the kinetics of cardiac biomarkers after ST-segment Elevation myocardial infarction
This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial